Associations Of Prenatal And Postnatal Growth With Insulin-Like Growth Factor-I Levels In Pre-Adolescence by Arathimos, Ryan et al.
                          Arathimos, R., Macdonald-Wallis, C., Bull, C., Holly, J. M. P., Oken, E.,
Kramer, M. S., ... Tilling, K. (2017). Associations Of Prenatal And Postnatal
Growth With Insulin-Like Growth Factor-I Levels In Pre-Adolescence.
Manuscript submitted for publication.
Peer reviewed version
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published




Associations of prenatal and postnatal growth with insulin-like growth factor-I levels in 
pre-adolescence 
Arathimos R 1,2, Macdonald-Wallis C1,2, Bull CJ1,2,3, Holly JMP3, Oken E4, Kramer MS5, 
Gusina N6, Bogdanovich N6, Vilchuck K6, Patel R1, Martin R M1, 2, 7 and Tilling K1,2  
 
1School of Social and Community Medicine, University of Bristol, Bristol, UK 
2Medical Research Council / University of Bristol Integrative Epidemiology Unit, University 
of Bristol, Bristol, UK   
3IGFs & Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, 
Bristol, UK 
4Division of Chronic Disease Research Across the Lifecourse, Department of Population 
Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, 
USA  
5Departments of Pediatrics and of Epidemiology, Biostatistics and Occupational Health, 
McGill University Faculty of Medicine, Montreal, Canada 
6National Research and Applied Medicine Mother and Child Centre, Minsk, Republic of 
Belarus 
7University of Bristol / University Hospitals Bristol NHS Foundation Trust National Institute 
for Health Research Bristol Nutrition Biomedical Research Unit, Bristol, UK. 
 
Sources of support:  PROBIT was supported by grants from the Canadian Institutes of 
Health Research (MOP - 53155), the US National Institute of Child Health and Development 
(R01 HD 050758), and the European Union's project on Early Nutrition Programming: Long-
term Efficacy and Safety Trials (FOOD-DT-2005-007036).  Dr. Oken was supported by US 
National Institutes of Health (K24 HD069408, P30 DK092924).  The Integrated 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/144493doi: bioRxiv preprint first posted online May. 31, 2017; 
2 
 
Epidemiology Unit is supported by the MRC and the University of Bristol 
(MC_UU_12013_2, MC_UU_12013_5 and MC_UU_12013_8).  The NIHR Bristol Nutrition 
Biomedical Research Unit (RMM) is funded by the National Institute for Health Research 
(NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and 
the University of Bristol. The funders had no role in the design and conduct of the study; 
collection, management, analysis, and interpretation of the data; and preparation, review, or 
approval of the manuscript. We are grateful to Dr Ying Foo for her help during the design 
and set up of the Promotion of Breastfeeding Intervention Trial (PROBIT). 
 
Trial registration:  Current Controlled Trials: ISRCTN37687716; Clinicaltrials.gov: 
NCT01561612 
 
Key words: IGF-I, growth, development, prenatal, postnatal, childhood, cohort study  
  
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 




Background: Rapid pre- and postnatal growth have been associated with later life adverse 
health outcomes, which could implicate (as a mediator) circulating insulin-like-growth-factor 
I (IGF-I), an important regulator of growth. We investigated associations of prenatal (birth 
weight and length) and postnatal growth in infancy and childhood with circulating IGF-I 
measured at 11.5 years of age. 
Methods: We analysed 11.5-year follow-up data from 17,046 Belarusian children who 
participated in the Promotion of Breastfeeding Intervention Trial (PROBIT) since birth.  
Results: Complete data were available for 5422 boys and 4743 girls (60%). We stratified the 
analyses by sex, as there was evidence of interaction between growth and sex in their 
associations with IGF-I. Weight and length/height velocity during childhood were positively 
associated with IGF-I at 11.5 years; associations increased with age at growth assessment and 
were stronger for length/height gain than for weight gain. The change in internal run-
normalized IGF-I z-score at 11.5 years was 0.038 (95% CI -0.004,0.080) per standard 
deviation (SD) increase in length gain at 0-3 months amongst girls and 0.025 (95% CI -
0.011,0.060) amongst boys, increasing to 0.336 (95% CI 0.281,0.391;) and 0.211 (95% CI 
0.165,0.256) for girls and boys, respectively, for growth during 6.5-11.5 years. 
Conclusion: Postnatal growth velocities in childhood are positively associated with levels of 
circulating IGF-I in pre-adolescents. Future studies should focus on assessing whether IGF-I 
is on the causal pathway between early growth and later health outcomes, such as cancer and 
diabetes. 
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Insulin-like growth factor I (IGF-I) is an important regulator of childhood growth and 
development and a part of the insulin-like growth factor (IGF) system, also known as the IGF 
axis. The system is comprised of two ligands (IGF-I and IGF-II) and six high-affinity binding 
proteins (IGFBP-1-6). Growth throughout childhood is controlled by growth hormone (GH), 
the effects of which are mediated by IGF-I. In animal models, IGF-I deficiency caused by 
mutations in the IGF-I gene leads to both intrauterine and postnatal growth failure(1), and in 
human studies, circulating IGF-I levels at birth are positively correlated with gestational age 
and birth weight standardized for gestational age(2). Rate of weight gain between birth and 2 
years of age is associated with IGF-I at 5 years of age(3). Infants with higher circulating IGF-I 
have higher previous and subsequent growth rates, and IGF-I levels correlate with subsequent 
weight gain(4). Weight and length/height at 1 year and 5 years of age have been associated 
with IGF-I levels at 25 years of age, indicating that IGF-I in adulthood may be related to 
growth in infancy(5). Under-nutrition in utero may lead to reprogramming of the IGF-I axis(6, 
7)
. This hypothesis is supported by evidence from both experimental models(8) and clinical 
paediatrics(9) . 
In later life, higher circulating levels of IGF-I are associated with breast, prostate and 
colorectal cancers(10-14), type 2 diabetes(15, 16) and (albeit less consistently) coronary heart 
disease(17-19). Anthropometric measures show robust associations with disease risk, for 
cancer, the risk of several cancers increases with height(20) and leg length(21), and IGF-I may 
act as an intermediate between growth and disease risk. Understanding the relationship 
between growth trajectories and IGF-I might inform understanding of disease mechanisms 
and assist in developing preventive or therapeutic interventions. 
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In the current study, we examine associations of anthropometric measures (weight and 
length/height) at birth and during childhood in relation to IGF-I levels measured in early 
adolescence. We use follow-up data from the Promotion of Breastfeeding Intervention Trial 
(PROBIT)(22) cohort, a cluster-randomized trial investigating the long-term effects of a 
breastfeeding promotion intervention on later health and development. 
METHODS 
The design of PROBIT has previously been reported in detail (23).  In brief, PROBIT enrolled 
17,046 infants born in 1996-7 at 31 maternity hospitals in the Republic of Belarus. Trial 
inclusion criteria required infants to be healthy singletons born at ≥37 weeks, with birth 
weight ≥2500g and Apgar score ≥5 at 5 minutes, whose mothers initiated breastfeeding and 
had no illness that would interfere with breastfeeding. Over 95% of mothers in the maternity 
hospitals chose to initiate breastfeeding, and approximately 98% of those consented to 
participate in the trial.  
The infants were followed up at 31 polyclinics (clinics providing outpatient paediatric 
healthcare) affiliated with the trial maternity hospitals at 1, 2, 3, 6, 9 and 12 months of age (n 
= 16,492; 96.7% response rate)(22), at mean age 6.5 years (n = 13,889; 81.5% response 
rate)(24) and at mean age 11.5 years (n = 13,879; 81.4% response rate)(25). 
Ethics 
PROBIT follow-up was approved by the Belarusian Ministry of Health and received ethical 
approval from the McGill University Health Centre Research Ethics Board; the Human 
Subjects Committee at Harvard Pilgrim Health Care; and the Avon Longitudinal Study of 
Parents and Children (ALSPAC) Law and Ethics Committee. A parent or legal guardian 
provided written informed consent in Russian at enrolment and at the follow-up visits, and all 
children provided written assent at the 11.5-year visit. 
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Measurements of growth 
Study paediatricians recorded clinically-measured weight and length during polyclinic visits 
at 1, 2, 3, 6, 9 and 12 months.  At 6.5 years of age, study paediatricians measured standing 
height up to four times with a wall-mounted stadiometer (Medtechnika, Pinsk, Belarus), and 
weight with an electronic digital scale (Bella 840; Seca Corporation, Hamburg, Germany).  
At 11.5 years of age, study paediatricians measured standing height and weight using the 
same techniques and instruments as at the 6.5-year visit. At the 6.5-year study visit, 
paediatricians also abstracted from the polyclinic record all clinical measures of weight and 
height from 12 months of age to 6.5 years. Training, quality assurance and audit procedures 
have been described in detail previously(26). 
Measurement of IGF-I 
Whole blood samples were collected at the 11.5-year research visit by finger prick onto 
Whatman 903 filter-paper cards by the polyclinic paediatricians, after at least 8 hours of 
fasting(27).  The cards were then allowed to dry and subsequently stored in freezers at each of 
the 31 polyclinic sites at -20°C until transport to the laboratory at the National Mother and 
Child Centre in Minsk, where they were stored at -80°C. The samples for IGF-I were stored 
at -20°C for a median of 1.7 months (interquartile range [IQR], 1.0-5.1) and at -80°C for a 
median of 18.4 months (IQR, 13.3-21.6). Circulating IGF-I was quantified from a single 3-
mm diameter disc (approx. 3 μL of blood) per child after a single thaw, using the validated 
method of Diamandi et al(28). Mean intra-assay coefficients of variation were 6%, 7%, and 
9% for low, medium, and high IGF-I values, respectively; the respective inter-assay values 
were 8%, 12%, and 16%. The stability and recoverability of IGF-I from such dried bloodspot 
methods in PROBIT has previously been reported(25). 
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IGF-I was assayed from 2 lots of reagents between January 2010 and November 2011 and, as 
we have noted previously(25), assay kits of different lot numbers vary in measured IGF-I. To 
remove the potential effect of between-lot or between-run variations, we standardized values 
of IGF-I within each assay run (n=43) by computing z-scores ([IGF-I value - mean for each 
run]/ SD for each run). 
Other variables 
Potential confounders considered in the analyses were maternal and paternal age at time of 
the birth of the index child, and maternal and paternal weight and height, as reported by the 
accompanying parent (usually the mother) at the 6.5 year follow-up. Mothers also reported 
maternal and paternal highest level of education and urban or rural residence at enrolment. 
Education was categorized into four levels as “complete university”, “advanced 
secondary/partial university”, “common secondary” and “incomplete secondary”. 
Confounders and other characteristics were tested for differences between excluded and 
included children using unpaired t-tests for continuous variables and chi-squared tests for 
categorical variables.  
Tanner stage, a scale of physical maturation in children that defines development based on 
external primary and secondary sex characteristics, such as the development of the breasts in 
girls, genital (testicular volume) size in boys and development of pubic hair in both girls and 
boys(29), were determined by direct physician examination at 11.5 years of age. Both Tanner 
stages for each sex (pubic hair and breast size for girls, pubic hair and genital size for boys) 
were used to adjust for pubertal onset in associations of growth rates with IGF-I stratified by 
sex.  
Statistical analysis  
Effects of post-natal growth velocity 
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Multilevel models were fitted using MLwinN v2.26 to estimate each child's sex-standardised 
growth velocity from birth to 11.5 years. Linear splines were used to describe the shape of the 
growth trajectories, with knot points (indicating where the linear slope changes) based on a 
previously derived model of the dataset, positioned at 3 months, 12 months and 2.8 years(30). 
The previous trajectories derived in PROBIT went up to only 60 months (5 years)(30); the 
model was extended in the current analysis to include data at 11.5 years and thus included an 
additional knot point at 6.5 years. The average trajectories were allowed to differ by sex by 
including a fixed effect of sex and interactions by sex with each of the splines. Individual-
level residuals were used to derive a predicted length and weight at birth, and rate of change 
in height and weight in each period of 0-3 months, 3-12 months, 1.1-2.8 years, 2.8-6.5 years 
and 6.5-11.5 years. These predicted growth rates were then used as the exposures in 
regression models with IGF-I at 11.5 years as the outcome. 
All postnatal growth models used sex-standardised change in length/height or weight as the 
exposure. Robust standard errors were used to allow for polyclinic clustering. Model 1 
adjusted for previous change(s) in length/height and exact age of the child at follow-up; 
model 2 adjusted additionally for parents’ anthropometry, age and education level; and model 
3 additionally for geographical location of the polyclinic (urban or rural; East or West of 
Belarus) and intervention arm. Stepwise adjustments for confounders in the 3 models ensured 
that parental covariates were adjusted for separately from confounding that relates to cohort 
design, such as trial arm and polyclinic location. As a sensitivity analysis for the growth 
models, a cross-sectional analysis at 11.5 years related observed height and weight at 11.5 
years to measured IGF-I levels using linear regression. Additionally, a further sensitivity 
analysis was carried out using multiple imputation(31, 32) to fill in missing values in covariates 
and IGF-I measurements. Imputation was performed in STATA 14.1 using the ICE process(33, 
34)
. We imputed 20 datasets to ensure estimate accuracy. Data was included for a total of 
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16,877 individuals that had attended at least 2 clinic visits, passed our quality-control (QC) 
and had recorded gender. 
To determine whether the association between early growth and IGF-I was mediated by 
pubertal timing, growth rate models were adjusted for Tanner-based pubertal stage at 11.5 
years of age in a separate model (Model 4). Although puberty cannot be a confounder of the 
growth-IGF-I association as it follows the previous measurement of growth, it may be a 
mediator of the growth-IGF-I association, particularly at 11.5 years, when many study 
children (especially girls) have entered puberty. To confirm that puberty was associated with 
in IGF-I in PROBIT, we also examined associations of Tanner stage with IGF-I at 11.5 years 
in girls and boys. 
In models adjusting for interactions of weight or height with size-for-gestational-age 
categories, p-values were calculated by taking the difference in log-likelihood between the 
models adjusting vs not adjusting for the multiple interaction terms and tested using the chi-
square statistic with 2 degrees of freedom. 
Effects of size at birth 
Categories of birth weight for gestational age were derived using a Canadian population-
based reference(35). Small-for-gestational-age (SGA) birth was defined as a birth weight 
<10th percentile for gestational age and sex, and large-for-gestational-age (LGA) birth was 
defined as a birth weight >90th percentile for gestational age and sex. Infants with birth 
weights between these extreme percentiles were classed as appropriate for gestational age 
(AGA).  
Linear regression models were fitted with birth weight-for-gestational-age categories as the 
exposure and IGF-I levels at 11.5 years as the outcome, accounting for clustering within the 
31 polyclinics using robust standard errors. The reference category was AGA. Associations 
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were estimated for both the whole sample and by sex, as growth rate residuals interacted with 
sex in their association with IGF-I.  
RESULTS 
Of the 17,046 infants originally recruited into PROBIT, a total of 10,165 (60%) with 
complete data on all exposures and confounders and with IGF-I measurements at 11.5 years 
were included in the analysis (Figure S1). All analyses were repeated on the full sample of 
12,356 individuals with available IGF-I measures but with missing confounders. Little 
difference was found between the results of complete case analysis and the full dataset. Table 
1 shows the baseline and follow-up characteristics of individuals in the analysis stratified by 
sex. Table S1 shows small differences between included versus excluded children in relation 
to geographical location and the educational attainment of the mothers and fathers.   
No statistical evidence of interaction between sex and birth weight for gestational age on 
IGF-I was found (p=0.36) in fully-adjusted models.  However, interaction tests of weight and 
height growth rate residuals with sex on IGF-I showed evidence of interaction at 2.8-6.5 
years and 6.5-11.5 years for IGF-I (p<0.001 for both). Hence, all results are presented 
separately by sex.  
The associations of sex-standardised length/height gain rate residuals with IGF-I at 11.5 years 
by sex are shown in Table 2. Neither birth length nor length gain velocity in the first 3 
months was associated with IGF-I levels at 11.5 years.  Associations of length/height gain 
with IGF-I were seen from 3 months onwards, however, and tended to be stronger in girls 
than in boys. The change in IGF-I z-score per SD change in length/height velocity between 
2.8-6.5 years for girls was 0.236 (95% CI 0.196,0.276), and per SD change in length/height 
velocity between 6.5-11.5 years was 0.336 (95% CI 0.281,0.391). These respective 
coefficients in boys were 0.186 (95% CI 0.153,0.219) and 0.211 (95% CI 0.165,0.256). 
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Associations between sex-standardised weight gain and IGF-I at 11.5 years, adjusted for 
previous measurements of height, are shown in Table 3. No associations were seen between 
birth weight and IGF-I levels at 11.5 years in boys; the change in IGF-I z-score per SD 
increase in birth weight was -0.007 (95% CI -0.044,0.032). An association was observed in 
girls, however: -0.065 (95% CI -0.115, -0.015). Amongst girls, no association was observed 
between weight gain velocity at 3-12 months of age and IGF-I (coefficient: 0.027; 95% CI: -
0.018,0.070), whereas a weak association was observed amongst boys (coefficient: 0.029; 
95% CI 0.006,0.053). Weight gain rates between 2.8-6.5 years were not associated with IGF-
I levels at age 11.5 years in boys; the changes in IGF-I z-score per SD increase in weight was 
0.023 (95% CI -0.014,0.058). At 6.5-11.5 years there was only a weak association with IGF-I 
(coefficient: 0.036; 95% CI 0.003,0.070). The associations at the same two time-points were 
stronger in girls however: 0.101 (95% CI 0.045,0.158) and 0.140 (95% CI 0.088,0.193), 
respectively. A sensitivity analysis using multiple imputation to fill in missing data in 16,877 
individuals revealed little difference in estimates when compared to the complete-case 
analysis (Table S7 and Table S8). Effect sizes for associations of length/height and weight 
growth rates with IGF-I in males increased marginally, whereas a small increase in effect 
sizes of weight growth rates in females was also evident. All effects were in the same 
direction as the complete cases analysis, except for birthweight and birth length/height in 
males which was reversed, with little evidence of an association in the imputed models for 
either. 
Adjusting for Tanner stage at outcome attenuated some of the associations between height 
growth rate and IGF-I in girls (Table S6). Attenuation of associations of height growth rate 
between 2.8-6.5 years and 6.5-11.5 years with IGF-I for boys was also observed. For weight 
gain rates, adjustment for puberty affected the association with IGF-I only marginally 
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between 2.8-6.5 years and 6.5-11.5 years in girls. However, adjustment for puberty increased 
the strength of the association somewhat between weight gain rates and IGF-I in boys. 
Cross-sectionally, height and weight at 11.5 years were positively associated with IGF-I 
concentrations in both girls and boys (Table S2). Adjustment for puberty attenuated some of 
the effect sizes (Model 4 Table S2). 
As expected, we observed a cross-sectional association between Tanner stage and IGF-I 
(Figure S2 & Table S5) with a 0.410 (95% CI 0.372,0.448) increase in z-score IGF-I per 
increase in Tanner stage for pubic hair development in girls and a 0.230 (95% CI  
0.195,0.266) increase in z-score IGF-I per increase in Tanner stage for pubic hair 
development in boys. Adjusting for current height and weight at 11.5 years attenuated the 
effect sizes somewhat (Model 3 Table S5) but the effects persisted for both girls and boys. 
No evidence for an association was found between birth weight-for-gestational-age categories 
and IGF-I z-score at 11.5 years in boys or girls. Compared to AGA births, the difference in 
IGF-I z-score in the fully-adjusted models (adjusted for age, birth-length, parent’s 
anthropometry /age /education, region and treatment arm) for girls born SGA was 0.086 
(95% CI -0.025, 0.197); for girls born LGA, the IGF-I z-score change was 0.004 (95% CI -
0.096, 0.103). For boys born SGA, the difference in IGF-I z-score was -0.007 (95% CI -
0.085, 0.071), and for those born LGA it was -0.034 (95% CI -0.127, 0.060) vs boys born 
AGA. Associations of birth weight-for-gestational-age categories with IGF-I levels at 11.5 
years, and of interactions of birth weight-for-gestational-age categories with both weight and 
height, are shown in Table S3. No interactions were observed with weight or height in girls 
or boys.  
DISCUSSION 
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In this prospective analysis of over 10,000 Belarusian children, we observed positive 
associations of postnatal length/height and weight velocity with IGF-I levels at 11.5 years. 
These associations were stronger for growth in later than in earlier childhood, with little or no 
association of weight or length at birth with later IGF-I.  In boys, weight gain during 2.8-6.5 
years and 6.5-11.5 years was not strongly associated with later IGF-I. However, girls showed 
stronger associations of IGF-I with growth between 2.8-6.5 and 6.5-11.5 years of age. In 
general, associations began later in childhood in girls than in boys. 
Observed associations attenuated once adjusted for Tanner stage. However, it is likely that 
puberty is a mediator of the relationship between growth and IGF-I, as rapid early growth 
may cause early onset of puberty, and IGF-I levels are higher during puberty. In this case, 
confounders of the puberty-IGF-I association will also become confounders of the  growth-
IGF-I associations, owing to collider bias(36, 37) induced by conditioning on pubertal stage. 
Furthermore, recent evidence from animal models suggests IGF-I is involved in the 
regulation of the onset of puberty(38). The biological pathways involved are likely complex, 
with many feedback loops involving both IGF-I and puberty onset. Further work is required 
on the subject before conclusions can be drawn about the exact role of IGF-I. A distinction 
should also be made between a statistical mediator and biological mediator. Whereas a 
confounding “third variable” could help explain an association between two other variables 
(which could be said to ‘cause’ the association), it may have nothing to do with the 
underlying biological cause or biological pathway. Causality and mediation can have 
different inferences when considered statistically vs biologically.  
Additionally, substantial variability has been observed between Tanner stages and other 
methods of assessing maturation or growth, such as peak height velocity (PHV), suggesting 
that Tanner stages may be an imprecise measure of pubertal onset(39). This may lead to 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/144493doi: bioRxiv preprint first posted online May. 31, 2017; 
14 
 
incomplete adjustment for puberty. The degree to which onset of puberty explains the 
observed associations may be studied through mediation analysis(40) in future work. 
Comparisons with previous studies 
IGF-I has an important role in regulating childhood growth. In agreement with our findings in 
PROBIT, children from the Avon Longitudinal Study of Parents and Children (ALSPAC) 
cohort who had greater gains in weight during early childhood had higher IGF-I levels at 5 
years(3). Specifically, an association between weight gain rate between 0–2 years and IGF-I at 
5 years was observed in ALSPAC. We observed similar associations in PROBIT between 
weight gain rate and IGF-I at 11.5 years for boys at 0-3 months, 3-12 months and 1.1-2.8 
years. However, for girls the same associations were not statistically significant at 0-3 months 
or 3-12 months. Instead, girls showed a strong association of IGF-I with weight gain rate in 
later childhood, i.e., at ages 2.8-6.5 years and 6.5-11.5 years. Our findings suggest substantial 
differences in magnitude of association between growth and IGF-I in girls vs boys. In 
ALSPAC, sex also appeared to modify the associations of IGF-I with leg growth, but the 
association was stronger in boys than in girls (p for interaction = 0.041)(41). In relation to 
programming effects in ALSPAC, IGF-I levels at 5 years were inversely related to birth 
weight(3). In PROBIT, a similar inverse association between birth weight and IGF-I at 11.5 
was found only in girls. No associations with size-for-gestational-age categories were found, 
however, suggesting that the association with crude birth weight in ALSPAC and PROBIT 
may have been driven by gestational age at birth. A study of 951 individuals followed from 
birth reported an association of IGF-I in early adult life (mean age of 25 years) with height at 
25 years of age and patterns of childhood growth but not with anthropometric measures at 
birth (including birthweight and birth length)(5). Similarly, we observed that birth length was 
not associated with IGF-I levels at 11.5 years in boys or girls and that birth weight was 
associated with IGF-I in girls (but not boys).  
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A historical cohort study based on 65 years of follow-up of 429 individuals found that neither 
height nor leg length in childhood or adulthood was associated with circulating levels of IGF-
I, IGF-II, or IGFBP-2 measured in late adulthood(42).  However, in the latter study, 
associations between components of height and IGF-I were all positive with wide confidence 
intervals, and thus are compatible with findings in PROBIT. Differences in ages between the 
two samples, however, make it difficult to draw conclusions, as IGF-I patterns change 
throughout life and many effects may have resolved by adulthood. 
Strengths and limitations 
Follow-up rates in PROBIT were high, minimising selection bias. However almost 28% of 
study children did not have measured IGF-I at 11.5 years. IGF-I was missing in individuals 
that did not attend clinic follow-up at 11.5 years. IGF-I was also not measured in individuals 
who did not provide enough blood sample for the assay or were excluded for technical 
reasons during quality control. The level of missing data on IGF-I could lead to biased 
associations if the likelihood of missing IGF-I is related to underlying IGF-I, conditional on 
the variables in the model, which we consider unlikely. A sensitivity analysis for the growth 
models using multiple imputation did not reveal substantial differences in estimates when 
compared to the complete cases analysis, indicating that any such bias is unlikely. The study 
sample population was sufficiently large to detect modest associations and interactions. 
Multiple measures of growth were available across infancy and childhood, and appropriate 
statistical methods were used to relate growth to IGF-I. 
Limitations include the fact that weight and length measurements in infancy were not taken 
according to a standardised protocol, which could lead to non-differential measurement error 
and thereby attenuate associations.  Uncertainty in the modelled estimation of the growth 
trajectories was not accounted for, and thus the width of the confidence intervals may be 
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underestimated. Measurement of IGF-I levels by dried blood spot may have led to 
measurement error; however, any error is again likely to be non-differential with respect to 
IGF-I and would therefore bias associations towards the null. Finally, the setting in Belarus 
may limit generalizability to other settings. 
CONCLUSION 
Postnatal growth velocity in Belarusian children was associated with higher circulating IGF-I 
at 11.5 years of age. The strength of the growth rate association with later-life IGF-I differed 
by sex. These results support the association between later-life IGF-I and childhood growth 
previously reported and support the hypothesis that IGF-I levels in childhood might mediate 
an association between anthropometric measures and disease in later-life. Future studies 
should assess whether IGF-I mediates the effect of early growth on later health. 
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Table 1 Baseline and follow-up characteristics of PROBIT children included in the current study by sex. 
 Girls (N=4,743) Boys (N=5,422) 
Height/length and weight - Mean (sd)   
Birth length cm  51.7 (2.1) 52.4 (2.2) 
Length/height at 3 months cm  60.4 (2.3) 61.6 (2.4) 
Height at 11.5 years cm  150.2 (7.9) 148.7 (7.4) 
Birth weight kg  3.4 (0.4) 3.5 (0.4) 
Weight at 3 months kg  5.9 (0.6) 6.3 (0.7) 
Weight at 11.5 years kg  40.9 (9.5) 40.6 (9.4) 
Region* - N (%)   
-East Urban 1,462 (30.8) 1,655 (30.5) 
-East Rural 755 (15.9) 791 (14.6) 
-West Urban 1,147 (24.2) 1,330 (24.5) 
-West Rural 1,379 (29.1) 1,646 (30.4) 
Maternal Education - N (%)   
-Complete University 686 (14.5) 740 (13.7) 
-Advanced Secondary/partial university 2,452 (51.7) 2,842 (52.4) 
-Common or incomplete Secondary 1,447 (30.5) 1,693 (31.2) 
-Incomplete Secondary 158 (3.3) 147 (2.7) 
Fathers Education - N (%)   
-Complete University 614 (13.0) 733 (13.5) 
-Advanced Secondary/partial University 2,288 (48.2) 2,577 (47.5) 
-Common or incomplete Secondary 1,749 (36.9) 2,005 (37.0) 
-Incomplete secondary 92 (1.9) 107 (2.0) 
Parental anthropometry - Mean (sd)   
Mothers weight kg  66.4 (12.6) 66.4 (12.5) 
Mothers height cm  164.5 (5.6) 164.9 (5.6) 
Fathers weight kg  79.6 (11.5) 78.0 (11.5) 
Fathers height cm 176.0 (6.6) 176.1 (6.6) 
Mothers age  25.2 (4.9) 25.1 (4.9) 
Fathers age 27.5 (5.1) 27.5 (5.1) 
Tanner stage; pubic hair development - N (%) 
Stage 1 1,448 (30.5) 2,883 (53.2) 
Stage 2 2,202 (46.4) 2,152 (39.7) 
Stage 3 971 (20.5) 355 (6.6) 
Stage 4 113 (2.4) 27 (0.5) 
Stage 5 9 (0.2) 5 (0.1) 
Tanner stage; female breast size/male genital size - N (%) 
Stage 1 601 (12.7) 727 (13.4) 
Stage 2 2,453 (51.7) 2,960 (54.6) 
Stage 3 1,466 (30.9) 1,546 (28.5) 
Stage 4 208 (4.3) 175 (3.2) 
Stage 5 20 (0.4) 14 (0.3) 
IGF-I at 11.5 years ng/ml - Mean (sd) 314.5 (124.9) 244.8 (92.2) 
* Regions of the Republic of Belarus divided in to East and West and by urban or rural housing tenure  
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Model 1 Model 2 Model 3 
 
 
Change in IGF-I z-score 
per SD increase in height 
(95% CI) 
Change in IGF-I z-score 
per SD increase in height 
(95% CI) 
Change in IGF-I z-score 
per SD increase in height 
(95% CI) 
Girls Birth 0.014 (-0.016,0.044) 0.004 (-0.028,0.037) 0.007 (-0.021, 0.035) 
 0-3 months 0.05 (0.001,0.099) 0.041 (-0.009,0.090) 0.038 (-0.004,0.080) 
 3-12 months 0.132 (0.095,0.170) 0.131 (0.093,0.170) 0.13 (0.092,0.168) 
 1.1-2.8 years 0.038 (0.004,0.071) 0.036 (0.003,0.069) 0.032 (-0.003,0.066) 
 2.8-6.5 years 0.219 (0.183,0.256) 0.236 (0.194,0.278) 0.236 (0.196,0.276) 
 6.5-11.5 years 0.333 (0.279,0.387) 0.337 (0.282,0.392) 0.336 (0.281,0.391) 
Boys Birth 0.002 (-0.031,0.034) -0.005 (-0.038,0.027) -0.005 (-0.037,0.026) 
 0-3 months 0.034 (-0.007,0.074) 0.023 (-0.017,0.064) 0.025 (-0.011,0.060) 
 3-12 months 0.119 (0.093,0.146) 0.115 (0.086,0.144) 0.113 (0.084,0.142) 
 1.1-2.8 years 0.032 (0.005,0.058) 0.03 (0.004,0.056) 0.032 (0.006,0.057) 
 2.8-6.5 years 0.176 (0.146,0.206) 0.184 (0.153,0.216) 0.186 (0.153,0.219) 
 6.5-11.5 years 0.208 (0.162,0.255) 0.212 (0.165,0.259) 0.211 (0.165,0.256) 
Three models with cumulative adjustments. Model 1 adjusted for age, birth length and previous measurement(s) of 
weight/height. Model 2 adjusted additionally for parents’ anthropometry, age, and education. Model 3 additionally for 
region and treatment arm. 
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Table 3 Associations of weight gain rates (sex-standardized) with IGF-I z-scores at 11.5 years. 
 
 
Model 1 Model 2 Model 3 
 
 
Change in IGF-I 
z-score per SD increase in 
weight (95% CI) 
Change in IGF-I 
z-score per SD increase in 
weight (95% CI) 
Change in IGF-I 
z-score per SD increase in 
weight (95% CI) 
Girls Birth -0.049(-0.107,0.01) -0.062(-0.118,-0.007) -0.065(-0.115,-0.015) 
 0-3 months 0.04(0.009,0.072) 0.037(0.006,0.067) 0.031(-0.002,0.063) 
 3-12 months 0.026(-0.015,0.067) 0.022(-0.022,0.065) 0.027(-0.018,0.07) 
 1.1-2.8 years 0.083(0.036,0.13) 0.079(0.032,0.127) 0.078(0.032,0.123) 
 2.8-6.5 years 0.11(0.051,0.17) 0.106(0.047,0.164) 0.101(0.045,0.158) 
 6.5-11.5 years 0.14(0.088,0.193) 0.14(0.088,0.192) 0.14(0.088,0.193) 
Boys Birth 0.003(-0.038,0.043) -0.008(-0.049,0.033) -0.007(-0.044,0.032) 
 0-3 months 0.049(0.025,0.073) 0.043(0.019,0.067) 0.045(0.02,0.07) 
 3-12 months 0.037(0.013,0.061) 0.031(0.006,0.057) 0.029(0.006,0.053) 
 1.1-2.8 years 0.048(0.024,0.072) 0.043(0.019,0.068) 0.043(0.018,0.067) 
 2.8-6.5 years 0.036(0.002,0.07) 0.022(-0.014,0.058) 0.023(-0.014,0.058) 
 6.5-11.5 years 0.045(0.011,0.08) 0.036(0.001,0.071) 0.036(0.003,0.07) 
Three models with cumulative adjustments. Model 1 adjusted for age, birth length and previous measurements of 
weight/height. Model 2 adjusted additionally for parents’ anthropometry, age, and education. Model 3 additionally for 
region and treatment arm. 
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